Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Breast Cancer, Metastatic HER2-negative Breast
Interventions: Cyclophosphamide, Mesothelin-targeted T cells, AP1903; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: chemotherapy, oral sodium phenylbutyrate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: End Stage Renal Disease, Renal Transplant
Interventions: Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Tolera Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more

Conditions: Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Interventions: mosunetuzumab, glofitamab, obinutuzumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Omaha, Nebraska • Philadelphia, Pennsylvania

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions: JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 9
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Hepatocellular Carcinoma
Interventions: AZD5851; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more

Conditions: Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions: SC291; Biological
Lead sponsor: Sana Biotechnology; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Jose, California + 10 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Rilvegostomig, Ramucirumab, Dato-DXd; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Santa Monica, California • Santa Rosa, California • Atlanta, Georgia + 3 more

Conditions: Common Variable Immunodeficiency
Interventions: STA-5326; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Interventions: Pembrolizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions: Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation; Biological · Other
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Tocilizumab; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: X-linked Severe Combined Immunodeficiency (XSCID)
Interventions: Campath, Palifermin, Busulfan, Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: CC-93269; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 5 more

Conditions: Relapsed CLL, Refractory CLL, Refractory Lymphoma
Interventions: BAFF CAR-T, Obinutuzumab, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Paolo Caimi, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atopic Dermatitis
Interventions: Oral Probiotics; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months to 3 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Cancer, Solid Tumor, Lymphoma
Interventions: Sym021, Sym022, Sym023; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: Xcellerated T Cells; Drug
Lead sponsor: Xcyte Therapies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Chronic Graft-versus-host Disease
Interventions: Interleukin-2; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Peripheral Arterial Disease
Interventions: Ixmyelocel-T, Placebo; Biological
Lead sponsor: Vericel Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 16 more

Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 479
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more

Conditions: Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions: CART22-65s cells, huCART19 Cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia
Interventions: Gamma Delta T-Cell Infusion; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

T-Cell Therapy for Advanced Breast Cancer

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

CAR-T Followed by Bispecific Antibodies

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Effect of Interleukin-2 on HIV Treatment Interruption

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Thymus Transplantation Dose in DiGeorge #932

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

The Effects of Probiotics in Atopic Dermatitis

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Xcellerated T CellsTM in Patients With Multiple Myeloma

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

CART22 Alone or in Combination With huCART19 for ALL

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT